PRGO News and Press, Perrigo Company plc From 11/06/19

Image source: The Motley Fool. Perrigo   (NYSE: PRGO) Q3 2019 Earnings Call Nov 06, 2019 , 8:00 a.m. ET Operator Continue reading

Perrigo Company plc (PRGO) Q3 2019 Results Earnings Conference Call November 6, 2019, 08:00 AM ET Company Participants Bradley Joseph - Vice President, Investor Relations Murray Kessler - President and Chief Executive Officer Raymond Silcock - Executive Vice President and Chief F...

Perrigo (NYSE: PRGO ): Q3 Non-GAAP EPS of $1.04 beats by $0.10 ; GAAP EPS of $0.67 beats by $0.09 . Revenue of $1.19B (+5.3% Y/Y) misses by $10M . Shares +0.4% PM. Press Release More news on: Perrigo Company plc, Earnings news and commentary, Healthcare stocks news,

DUBLIN , Nov. 6, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care Products TM " , today announced financial results for the third quarter ended September 28, 2019. President and CEO Murray S. K...

AES , ALE , AMRX , ANIP , AYR , BCOR , BKI , BLMN , BR , CARS , CBRE , CNHI , CNR , COTY , CPRI , CRCM , CRL , CSTE , CVIA , CVS , CWEN , CYBR , DEA , DNOW , DOC , ELAN , ENBL , ESPR , FUN , GCP , GEL , GIB , GLOG , GOLD , HUM , HZNP , IMOS , IONS , JE...

Perrigo (NYSE: PRGO ) is scheduled to announce Q3 earnings results on Wednesday, November 6th, before market open. The consensus EPS Estimate is $0.94 (-13.8% Y/Y) and the consensus Revenue Estimate is $1.2B (+6.2% Y/Y). Over the last 2 years, prgo has beaten EPS estimates 88% of the...

In a statement , the FDA says chronic shortages of certain medicines in the U.S. have not produced the expected responses from drugmakers that traditional economics predict, specifically, increasing prices to reflect a supply/demand imbalance aimed at achieving profitable production to sati...

DUBLIN , Oct. 23, 2019 /PRNewswire/ -- As a precautionary measure, Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack sizes). The recall is being taken due to possible...

Quick Take Phathom Pharmaceuticals ( PHAT ) intends to raise $150 million from an IPO, per an S-1/A registration statement . The company is advancing a drug treatment for GERD, a common gastrointestinal condition. For life science investors with at least a 24-month hold timeframe, the I...

DUBLIN , Oct. 15, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019 . The Company will host a conference call beginning at 8:00 a.m. (EDT) . The...